Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
Status:
Completed
Trial end date:
2017-12-12
Target enrollment:
Participant gender:
Summary
This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence
of systemic inflammation. Half of participants will receive NP001 and the other half will
receive placebo.